What is the appropriate management of diabetes mellitus?

Management of Diabetes Mellitus

Start metformin at diagnosis alongside lifestyle modifications for all patients with type 2 diabetes unless contraindicated, and add SGLT2 inhibitors or GLP-1 receptor agonists early—potentially from diagnosis—to provide organ protection and improve long-term outcomes. 1, 2, 3, 4

Initial Pharmacologic Therapy

First-Line Treatment

• Metformin is the optimal first-line agent for type 2 diabetes due to its efficacy, safety profile, and cost-effectiveness 1, 5
• Start at low dose (e.g., 500 mg once or twice daily) and titrate gradually to minimize gastrointestinal side effects 1
• Initiate at or soon after diagnosis, especially when lifestyle intervention alone is unlikely to achieve HbA1c goals 1

When to Start Insulin Immediately

Bypass oral agents and start insulin from the outset when:

• Blood glucose >300-350 mg/dL (16.7-19.4 mmol/L) 1
• HbA1c ≥10-12% 1
• Presence of catabolic features (weight loss, ketosis) 1
• Ketonuria is present 1
• Patient is markedly symptomatic 1

Early Combination Therapy for Organ Protection

The 2026 consensus represents a paradigm shift: SGLT2 inhibitors and/or GLP-1-based therapies should be considered from diagnosis, not just when metformin fails 4. This earlier approach provides:

• Cardiovascular protection
• Kidney protection
• Heart failure risk reduction
• Weight management benefits

For patients with established cardiovascular disease, chronic kidney disease, or heart failure, use combination therapy with SGLT2 inhibitors AND GLP-1-based therapies from the start 4

Advancing Therapy When Targets Are Not Met

Dual Therapy (if HbA1c remains above target on metformin)

Add one of the following based on comorbidities 2, 3:

Priority agents for patients with:

• ASCVD or high cardiovascular risk: GLP-1 RA (semaglutide, dulaglutide) or SGLT2 inhibitor 2, 3
• Heart failure: SGLT2 inhibitor (first choice) 2, 3
• Chronic kidney disease: SGLT2 inhibitor (first choice) 2, 3
• Obesity: Tirzepatide (dual GIP/GLP-1 RA) or semaglutide (highest efficacy for weight loss) 3

For patients without these comorbidities:

• Consider DPP-4 inhibitors, sulfonylureas, or thiazolidinediones based on cost, hypoglycemia risk, and weight considerations 2

Triple Therapy

If dual therapy fails to achieve targets after 3-6 months, add a third agent with complementary mechanism of action 1, 2

Insulin Therapy

Initiate basal insulin when:

• Combination oral/injectable therapy fails to achieve glycemic targets 1, 3
• Progressive beta-cell failure occurs 1

Starting regimen:

• Begin with basal insulin (NPH, glargine, detemir, or degludec) at 10 units or 0.1-0.2 units/kg 6
• Continue metformin and consider continuing SGLT2 inhibitors or thiazolidinediones for metabolic benefits 2
• Discontinue sulfonylureas, DPP-4 inhibitors, and usually GLP-1 RAs when advancing to complex insulin regimens (beyond basal insulin alone) 6

When basal insulin is optimized but HbA1c remains elevated:

• Add prandial rapid-acting insulin (lispro, aspart, glulisine) before meals 1, 6
• Alternatively, add or intensify GLP-1 RA therapy 2

Watch for overbasalization: basal dose >0.5 units/kg/day, significant bedtime-to-morning glucose differential, hypoglycemia, or high glycemic variability warrant prompt reevaluation 2

Lifestyle Modifications (Foundation of All Therapy)

Medical Nutrition Therapy

• Individualized meal planning—no single eating pattern fits all 7
• Emphasize minimally processed plant foods: whole grains, vegetables, whole fruits, legumes, nuts, seeds 8
• Minimize red/processed meats, sugar-sweetened beverages, refined grains, sodium 8
• Referral to registered dietitian associated with HbA1c reductions of 0.3-2% in type 2 diabetes 7
• For hospitalized patients, consistent carbohydrate meal plans facilitate insulin dosing 9

Physical Activity

• At least 60 minutes daily of moderate-to-vigorous exercise for children/adolescents 10
• Limit non-academic screen time to <2 hours daily 10
• Physical activity is essential for weight loss maintenance 5

Weight Management

• Weight loss recommended for all overweight/obese individuals with diabetes 5
• Low-carbohydrate, low-fat calorie-restricted, or Mediterranean diets all effective short-term (up to 2 years) 5
• Intensive lifestyle programs with frequent follow-up achieve significant weight reduction 7

Glycemic Targets

General Adult Targets

• HbA1c <7% for most non-pregnant adults to reduce microvascular complications 5
• More stringent target (<6.5%) for patients with short diabetes duration, long life expectancy, no significant CVD, if achievable without hypoglycemia 5
• Less stringent target (<8%) for patients with history of severe hypoglycemia, limited life expectancy, advanced complications, extensive comorbidities 5

Monitoring Frequency

• HbA1c every 3 months when therapy changes or goals not met 5, 10, 5
• HbA1c at least twice yearly when meeting goals with stable control 5

Special Populations

Children and Adolescents with Type 2 Diabetes

At diagnosis, initiate:

• Lifestyle modification program (nutrition and physical activity) 10
• Metformin as first-line therapy 10

Start insulin immediately if:

• Ketotic or in diabetic ketoacidosis 10
• Random glucose ≥250 mg/dL 10
• HbA1c >9% 10
• Distinction between type 1 and type 2 unclear 10

Hospitalized Patients

Hypoglycemia prevention is critical:

• 84% of patients with severe hypoglycemia (<40 mg/dL) had preceding hypoglycemia (<70 mg/dL) during same admission 9, 11
• Common preventable causes: insulin dosing errors, nutrition-insulin mismatch, inappropriate management of first hypoglycemia episode 9, 11
• Acute kidney injury increases hypoglycemia risk (decreased insulin clearance) 9

Insulin regimens for enteral/parenteral nutrition:

• Cover basal, prandial, and correctional needs 9
• Type 1 diabetes patients must continue basal insulin even if feedings discontinued 9
• For enteral nutrition: calculate 1 unit insulin per 10-15 g carbohydrate in formula 9
• Use NPH insulin 2-3 times daily or regular insulin every 6 hours for correctional coverage 9
• If nutrition interrupted, start 10% dextrose infusion immediately to prevent hypoglycemia 9

Perioperative management:

• Withhold metformin day of surgery 11
• Give half of NPH dose or 60-80% of long-acting analog dose 11
• Monitor glucose every 4-6 hours while NPO 11
• Target glucose 80-180 mg/dL perioperatively (tighter targets increase hypoglycemia without improving outcomes) 11
• Basal-bolus insulin superior to sliding scale alone for noncardiac surgery 11

Self-management in hospital may be appropriate for select patients who successfully self-manage at home, have adequate cognitive/physical skills, stable insulin requirements, and understand sick-day management 9, 11

Critical Pitfalls to Avoid

1. Clinical inertia: Intensify therapy every 2-3 months if targets not met 1
2. Insulin as threat: Frame insulin as effective tool, not punishment for failure 3
3. Ignoring hypoglycemia patterns: 75% of patients with hypoglycemia had no basal insulin dose adjustment before next administration 11
4. Nutrition-insulin mismatch: Most common in hospital when feedings unexpectedly interrupted 9, 11
5. Continuing sulfonylureas with complex insulin regimens: Reassess need to minimize hypoglycemia risk 2
6. Delaying combination therapy: Patients with HbA1c ≥9% have low probability of achieving target with monotherapy—start combination therapy from diagnosis 1

Patient Education Requirements

All patients require comprehensive diabetes self-management education (DSME) at diagnosis and ongoing 7, 5:

• Glucose monitoring techniques
• Insulin injection technique and storage (if applicable)
• Recognition and treatment of hypoglycemia
• Sick-day management rules
• Carbohydrate estimation
• Medication adherence strategies

DSME is associated with: improved diabetes knowledge, self-care behaviors, lower HbA1c, reduced mortality, improved quality of life, reduced healthcare costs 7

Cost Considerations

When financial barriers exist:

• Use lower-cost medications: metformin, sulfonylureas, thiazolidinediones, human insulin 2
• Balance cost against risks of hypoglycemia, weight gain, cardiovascular/kidney events 2
• Clinicians and social services should collaborate to implement cost-reduction strategies 2